Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands

Executive Summary

Liz Barrett joined Novartis in February after leading Pfizer's oncology unit, taking over leadership of the business at a time of transition and tasked with building new blockbusters as old reliable work engines mature. She talked to Scrip about her plans for Novartis Oncology at ASCO.

Advertisement

Related Content

Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern
AAA Ramps Up Lutathera Launch And Plans Expansion Under Novartis Ownership
CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie
ASCO 2018: Optimism As Industry Resets And Looks To What Is Next
Lutathera Approval Positions Novartis To Regain NET Share Taken By Ipsen
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Novartis Rejiggers Pharma To Favor Oncology
Novartis taps Penn University for cancer immunotherapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123216

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel